The Molecular Oncology Program of the University of California, Davis Cancer Center is focused on understanding fundamental processes associated with carcinogenesis and the molecular and cell biology of cancer cells. Within this framework the program integrates two distinct but related and mutually reinforcing areas, oncogenic signals and chromosome biology. Of particular interest is how cellular signals regulate chromatin remodeling with respect to the assembly of nuclear hormone receptors and DNA repair complexes. Genome instability is a common denominator for most, if not all, cancers, and misregulated signaling pathways are often the root cause for malignant transformation. Two central themes, 1) Cytoplasmic Signaling and Chromosome Dynamics and 2) Nuclear Signaling and Chromosome Stability, integrate a distinguished group of investigators. The programmatic goals are: 1) Discovery of critical molecules involved in the signaling to and function of transcriptional and DNA repair/recombination complexes In cancer cells; 2) Identification of critical molecules in signaling and function of transcription and DNA repair as potential predictive markers and therapeutic targets in cancer; 3) Collaboration with other programs to facilitate translational research originating in the basic scientific discoveries of the Molecular Oncology Program. The program has 35 members from 10 different academic units of UC Davis and LLNL. It has 16 NCl-funded projects for $2.4 million ADC (total peer-reviewed funding, $10.7 million ADC). The group has 449 publications for the last funding period; 22% are inter-programmatic and 10% are intra-programmatic.

Public Health Relevance

To Improve survival from cancer, more fundamental information must be gained. This program contributes to this task by discovering how cells alter the way In which they signal as they move from normal to cancer. The program also focuses on understanding how DNA Is repaired. DNA repair may initially stop cancers developing;however, after cancer is present, alterations in DNA repair may influence the tumor's response to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-10S2
Application #
8567249
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-07-01
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$26,299
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications